Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

Abstract

Tacrolimus, at dosages of 1.5-3 mg/day, was found to be effective in DMARD-resistant or -intolerant patients with active RA.

Solid state compatibility study and characterization of a novel degradation product of tacrolimus in formulation

“…As a potent immunosuppressant it is widely used for graft rejection prevention after organ transplantation [4][5][6]. TAC is also used in the treatment of autoimmune diseases [7][8][9][10][11] and atopic dermatitis [12][13][14].…”

Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis

“…Tacrolimus is efficacious in the management of organ transplant [14] and in the treatment of autoimmune diseases such as systemic lupus erythematosus [15] and rheumatoid arthritis [16]. Successful treatment with tacrolimus in patients with PM/DM has also been reported for refractory myositis [17,18] and ILD [18][19][20].…”

Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus

“…Because T-cell activation has a key role in the pathogenesis of RA, randomized clinical trials for TAC monotherapy or in combination therapy with methotrexate (MTX) in patients with RA have shown the remarkable efficacy and safety [ 22 - 25 ]. Thus, TAC can be applied as an additional therapeutic option for RA [ 21 , 26 ]. After TAC was approved for the first time in the world for treating RA in Canada in February 2004, it was also available as a DMARD for patients with RA in Japan and South Korea in April 2005 and October 2008, respectively.…”